AKBA
Akebia Therapeutics, Inc.
Price Chart
Latest Quote
$1.38
Current Price| Previous Close | $1.41 |
| Open | $1.39 |
| Day High | $1.43 |
| Day Low | $1.37 |
| Volume | 3,759,914 |
Stock Information
| Shares Outstanding | 265.37M |
| Total Debt | $199.01M |
| Cash Equivalents | $166.44M |
| Revenue | $225.07M |
| Net Income | $-15.90M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $366.21M |
| EPS (TTM) | $-0.08 |
| Exchange | NCM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | -0.97 |
| Debt to Earnings | 0.49 |
| Current Ratio | 1.41 |
| Quick Ratio | 1.07 |
| Avg Revenue Growth | -6.08% |
| Profit Margin | -43.33% |
| Return on Equity | 141.12% |
| Avg FCF Growth | -20.98% |
| FCF Yield | -11.11% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.38 | 3,805,800 |
| 2026-01-30 | $1.41 | 2,307,800 |
| 2026-01-29 | $1.45 | 1,812,300 |
| 2026-01-28 | $1.45 | 2,414,700 |
| 2026-01-27 | $1.51 | 2,578,100 |
| 2026-01-26 | $1.43 | 3,259,400 |
| 2026-01-23 | $1.36 | 4,175,500 |
| 2026-01-22 | $1.44 | 2,373,100 |
| 2026-01-21 | $1.37 | 2,105,500 |
| 2026-01-20 | $1.34 | 2,463,400 |
| 2026-01-16 | $1.36 | 2,766,800 |
| 2026-01-15 | $1.34 | 2,478,900 |
| 2026-01-14 | $1.38 | 3,215,600 |
| 2026-01-13 | $1.38 | 4,544,400 |
| 2026-01-12 | $1.40 | 6,780,800 |
| 2026-01-09 | $1.52 | 2,647,200 |
| 2026-01-08 | $1.49 | 3,581,100 |
| 2026-01-07 | $1.53 | 2,699,600 |
| 2026-01-06 | $1.47 | 2,871,800 |
| 2026-01-05 | $1.51 | 2,157,000 |
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Akebia announces first patient dosed in Phase 2 trial of praliciguat
TipRanks âĸ 2026-01-07T13:22:48Z
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Insider Monkey âĸ 2025-12-28T17:46:11Z
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Simply Wall St. âĸ 2025-12-11T11:14:15Z
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
Barchart âĸ 2025-12-02T16:28:21Z
Top Midday Gainers
MT Newswires âĸ 2025-12-01T18:32:48ZAkebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
MT Newswires âĸ 2025-12-01T13:40:54ZWhy Is Akebia (AKBA) Up After Strong Vafseo Data and Surging Q3 2025 Revenue?
Simply Wall St. âĸ 2025-11-14T07:14:36Z
Implied Volatility Surging for Akebia Therapeutics Stock Options
Zacks âĸ 2025-11-13T16:01:00Z
Akebia Therapeutics (AKBA): Valuation Insights Following Q3 Profit Surge and Positive Vafseo Clinical Update
Simply Wall St. âĸ 2025-11-12T13:11:28Z
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
Zacks âĸ 2025-11-11T15:10:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $63,177,000 | $74,149,000 | $85,568,000 | $150,671,000 |
| Cost Of Revenue | $63,177,000 | $74,149,000 | $85,568,000 | $150,671,000 |
| Total Revenue | $160,180,000 | $194,623,000 | $292,484,000 | $211,650,000 |
| Operating Revenue | $160,180,000 | $194,623,000 | $292,484,000 | $211,650,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $18,185,000 | $6,032,000 | $15,687,000 | $19,936,000 |
| Total Expenses | $210,594,000 | $240,698,000 | $357,330,000 | $476,152,000 |
| Other Income Expense | $-811,000 | $182,000 | $-13,693,000 | $2,414,000 |
| Other Non Operating Income Expenses | $94,000 | $887,000 | $3,146,000 | $2,414,000 |
| Net Non Operating Interest Income Expense | $-18,185,000 | $-6,032,000 | $-15,687,000 | $-19,936,000 |
| Interest Expense Non Operating | $18,185,000 | $6,032,000 | $15,687,000 | $19,936,000 |
| Operating Expense | $147,417,000 | $166,549,000 | $271,762,000 | $325,481,000 |
| Other Operating Expenses | $3,220,000 | $3,237,000 | $3,175,000 | $3,489,000 |
| Selling And Marketing Expense | - | $100,233,000 | $138,601,000 | $174,140,000 |
| Total Other Finance Cost | - | - | $15,687,000 | $19,936,000 |
| General And Administrative Expense | - | - | $141,874,000 | $177,650,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Net Interest Income | $-18,185,000 | $-6,032,000 | $-15,687,000 | $-19,936,000 |
| Normalized Income | $-68,505,000 | $-51,220,000 | $-77,387,000 | $-282,024,000 |
| Net Income From Continuing And Discontinued Operation | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Total Operating Income As Reported | $-50,472,000 | $-46,256,000 | $-80,779,000 | $-264,502,000 |
| Net Income Common Stockholders | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Net Income | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Net Income Including Noncontrolling Interests | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Net Income Continuous Operations | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Pretax Income | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Special Income Charges | $-575,000 | $-705,000 | $-16,839,000 | $0 |
| Operating Income | $-50,414,000 | $-46,075,000 | $-64,846,000 | $-264,502,000 |
| Gross Profit | $97,003,000 | $120,474,000 | $206,916,000 | $60,979,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.33 | $-0.28 | $-0.51 | $-1.70 |
| Basic EPS | $-0.33 | $-0.28 | $-0.51 | $-1.70 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,816,000 | $-7,561,000 | $-24,003,000 | $-226,532,000 |
| Total Unusual Items | $-905,000 | $-705,000 | $-16,839,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-905,000 | $-705,000 | $-16,839,000 | $0 |
| Reconciled Depreciation | $37,504,000 | $37,627,000 | $37,697,000 | $37,970,000 |
| EBITDA (Bullshit earnings) | $-13,721,000 | $-8,266,000 | $-40,842,000 | $-226,532,000 |
| EBIT | $-51,225,000 | $-45,893,000 | $-78,539,000 | $-264,502,000 |
| Diluted Average Shares | $210,946,658 | $187,465,448 | $182,782,680 | $165,949,695 |
| Basic Average Shares | $210,946,658 | $187,465,448 | $182,782,680 | $165,949,695 |
| Diluted NI Availto Com Stockholders | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Other Special Charges | $517,000 | $524,000 | $906,000 | - |
| Restructuring And Mergern Acquisition | $58,000 | $181,000 | $15,933,000 | $0 |
| Gain On Sale Of Security | $-330,000 | - | - | - |
| Research And Development | $37,652,000 | $63,079,000 | $129,986,000 | $147,852,000 |
| Selling General And Administration | $106,545,000 | $100,233,000 | $138,601,000 | $174,140,000 |
| Tax Provision | - | - | $0 | $0 |
| Other Gand A | - | - | $141,874,000 | $177,650,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-108,229,000 | $-125,670,000 | $-125,898,000 | $-93,163,000 |
| Total Assets | $220,670,000 | $241,703,000 | $356,054,000 | $529,347,000 |
| Total Non Current Assets | $106,839,000 | $123,554,000 | $170,872,000 | $258,198,000 |
| Other Non Current Assets | $37,377,000 | $12,423,000 | $5,372,000 | $50,421,000 |
| Goodwill And Other Intangible Assets | $59,044,000 | $95,086,000 | $131,128,000 | $167,171,000 |
| Current Assets | $113,831,000 | $118,149,000 | $185,182,000 | $271,149,000 |
| Other Current Assets | $7,321,000 | $5,754,000 | $32,864,000 | $33,140,000 |
| Prepaid Assets | $4,029,000 | $14,489,000 | - | $33,140,000 |
| Inventory | $16,243,000 | $15,691,000 | $21,568,000 | $36,628,000 |
| Receivables | $34,368,000 | $39,290,000 | $40,284,000 | $51,581,000 |
| Accounts Receivable | $34,368,000 | $39,290,000 | $40,284,000 | $51,581,000 |
| Allowance For Doubtful Accounts Receivable | $-1,212,000 | $-1,029,000 | - | - |
| Gross Accounts Receivable | $35,580,000 | $40,319,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $51,870,000 | $42,925,000 | $90,466,000 | $149,800,000 |
| Cash And Cash Equivalents | $51,870,000 | $42,925,000 | $90,466,000 | $149,800,000 |
| Other Intangible Assets | - | $36,042,000 | $72,084,000 | $108,127,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $47,640,000 | $48,121,000 | $99,783,000 | $136,048,000 |
| Long Term Debt And Capital Lease Obligation | $42,240,000 | $26,130,000 | $63,039,000 | $33,703,000 |
| Long Term Debt | $38,693,000 | $17,183,000 | $34,078,000 | - |
| Current Debt And Capital Lease Obligation | $5,400,000 | $21,991,000 | $36,744,000 | $102,345,000 |
| Current Debt | - | $17,500,000 | $32,000,000 | $97,543,000 |
| Other Current Borrowings | - | $17,500,000 | $32,000,000 | $97,543,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $269,855,000 | $272,287,000 | $350,824,000 | $455,339,000 |
| Total Non Current Liabilities Net Minority Interest | $188,941,000 | $172,417,000 | $221,288,000 | $194,288,000 |
| Other Non Current Liabilities | $103,512,000 | $62,898,000 | $73,201,000 | $137,291,000 |
| Derivative Product Liabilities | $5,176,000 | $0 | $760,000 | $1,820,000 |
| Non Current Deferred Liabilities | $0 | $43,296,000 | $43,296,000 | $21,474,000 |
| Current Liabilities | $80,914,000 | $99,870,000 | $129,536,000 | $261,051,000 |
| Other Current Liabilities | $6,114,000 | $4,602,000 | $6,576,000 | - |
| Payables And Accrued Expenses | $39,184,000 | $36,701,000 | $36,527,000 | $106,618,000 |
| Payables | $15,180,000 | $14,635,000 | $18,021,000 | $33,588,000 |
| Accounts Payable | $15,180,000 | $14,635,000 | $18,021,000 | $33,588,000 |
| Current Deferred Liabilities | - | $0 | $3,738,000 | $20,906,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-49,185,000 | $-30,584,000 | $5,230,000 | $74,008,000 |
| Total Equity Gross Minority Interest | $-49,185,000 | $-30,584,000 | $5,230,000 | $74,008,000 |
| Stockholders Equity | $-49,185,000 | $-30,584,000 | $5,230,000 | $74,008,000 |
| Gains Losses Not Affecting Retained Earnings | $6,000 | $6,000 | $6,000 | $6,000 |
| Other Equity Adjustments | $6,000 | $6,000 | $6,000 | $6,000 |
| Retained Earnings | $-1,678,360,000 | $-1,608,950,000 | $-1,557,025,000 | $-1,462,799,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $224,848,992 | $194,582,539 | $184,135,714 | $177,000,963 |
| Share Issued | $224,848,992 | $194,582,539 | $184,135,714 | $177,000,963 |
| Tangible Book Value | $-108,229,000 | $-125,670,000 | $-125,898,000 | $-93,163,000 |
| Invested Capital | $-10,492,000 | $4,099,000 | $71,308,000 | $171,551,000 |
| Working Capital | $32,917,000 | $18,279,000 | $55,646,000 | $10,098,000 |
| Capital Lease Obligations | $8,947,000 | $13,438,000 | $33,705,000 | $38,505,000 |
| Total Capitalization | $-10,492,000 | $-13,401,000 | $39,308,000 | $74,008,000 |
| Additional Paid In Capital | $1,629,167,000 | $1,578,358,000 | $1,562,247,000 | $1,536,800,000 |
| Capital Stock | $2,000 | $2,000 | $2,000 | $1,000 |
| Common Stock | $2,000 | $2,000 | $2,000 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $43,296,000 | $43,296,000 | $21,474,000 |
| Long Term Capital Lease Obligation | $3,547,000 | $8,947,000 | $28,961,000 | $33,703,000 |
| Long Term Provisions | $38,013,000 | $40,093,000 | $40,992,000 | - |
| Current Capital Lease Obligation | $5,400,000 | $4,491,000 | $4,744,000 | $4,802,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,194,000 | $8,216,000 | $11,894,000 | - |
| Current Provisions | $21,022,000 | $28,360,000 | $34,057,000 | $31,182,000 |
| Current Accrued Expenses | $24,004,000 | $22,066,000 | $18,506,000 | $73,030,000 |
| Goodwill | $59,044,000 | $59,044,000 | $59,044,000 | $59,044,000 |
| Net PPE | $10,418,000 | $16,045,000 | $34,372,000 | $40,606,000 |
| Gross PPE | $10,418,000 | $16,045,000 | $34,372,000 | $48,271,000 |
| Other Properties | $10,418,000 | $16,045,000 | $34,372,000 | $36,602,000 |
| Finished Goods | $4,212,000 | $11,394,000 | $13,676,000 | - |
| Work In Process | $12,031,000 | $4,297,000 | $7,892,000 | - |
| Current Deferred Revenue | - | $0 | $3,738,000 | $20,906,000 |
| Accumulated Depreciation | - | - | $-9,319,000 | $-7,665,000 |
| Leases | - | - | $8,687,000 | $8,573,000 |
| Machinery Furniture Equipment | - | - | $3,096,000 | $3,096,000 |
| Properties | - | - | $0 | $0 |
| Other Short Term Investments | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-40,692,000 | $-23,384,000 | $-73,268,000 | $-253,024,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-40,659,000 | $-23,384,000 | $-73,154,000 | $-252,965,000 |
| Cash Flow From Continuing Operating Activities | $-40,659,000 | $-23,384,000 | $-73,154,000 | $-252,965,000 |
| Operating Gains Losses | $624,000 | $-760,000 | $-654,000 | $-600,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-33,000 | - | $-114,000 | $-59,000 |
| Investing Cash Flow | $-33,000 | $0 | $-114,000 | $39,941,000 |
| Cash Flow From Continuing Investing Activities | $-33,000 | $0 | $-114,000 | $39,941,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-1,272,000 | $0 | - | $0 |
| Issuance Of Capital Stock | $42,649,000 | $6,793,000 | $7,531,000 | $88,948,000 |
| Financing Cash Flow | $49,663,000 | $-25,206,000 | $14,598,000 | $133,731,000 |
| Cash Flow From Continuing Financing Activities | $49,663,000 | $-25,206,000 | $14,598,000 | $133,731,000 |
| Net Common Stock Issuance | $41,377,000 | $6,793,000 | $7,531,000 | $88,948,000 |
| Common Stock Issuance | $42,649,000 | $6,793,000 | $7,531,000 | $88,948,000 |
| Net Other Financing Charges | - | - | $40,000,000 | $44,783,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-37,099,000 | $-32,000,000 | $-33,000,000 | $0 |
| Issuance Of Debt | $45,000,000 | $0 | $0 | $0 |
| Interest Paid Supplemental Data | $5,035,000 | $6,059,000 | $6,755,000 | $9,632,000 |
| End Cash Position | $53,550,000 | $44,579,000 | $93,169,000 | $151,839,000 |
| Beginning Cash Position | $44,579,000 | $93,169,000 | $151,839,000 | $231,132,000 |
| Changes In Cash | $8,971,000 | $-48,590,000 | $-58,670,000 | $-79,293,000 |
| Proceeds From Stock Option Exercised | $385,000 | $1,000 | $67,000 | $0 |
| Common Stock Payments | $-1,272,000 | $0 | - | $0 |
| Net Issuance Payments Of Debt | $7,901,000 | $-32,000,000 | $-33,000,000 | $0 |
| Net Long Term Debt Issuance | $7,901,000 | $-32,000,000 | $-33,000,000 | $0 |
| Long Term Debt Payments | $-37,099,000 | $-32,000,000 | $-33,000,000 | $0 |
| Long Term Debt Issuance | $45,000,000 | $0 | $0 | $0 |
| Net PPE Purchase And Sale | $-33,000 | $0 | $-114,000 | $-59,000 |
| Purchase Of PPE | $-33,000 | $0 | $-114,000 | $-59,000 |
| Change In Working Capital | $-39,676,000 | $-20,727,000 | $-1,443,000 | $-105,611,000 |
| Change In Other Current Liabilities | $-10,695,000 | $-10,654,000 | $4,588,000 | $2,229,000 |
| Change In Other Current Assets | $622,000 | $-1,361,000 | $-5,623,000 | $-8,214,000 |
| Change In Payables And Accrued Expense | $-14,141,000 | $-15,265,000 | $-36,504,000 | $-33,815,000 |
| Change In Accrued Expense | $-12,777,000 | $-10,021,000 | $-38,005,000 | $-22,080,000 |
| Change In Payable | $-1,364,000 | $-5,244,000 | $1,501,000 | $-11,735,000 |
| Change In Account Payable | $-1,364,000 | $-5,244,000 | $1,501,000 | $-11,735,000 |
| Change In Prepaid Assets | $8,893,000 | $11,839,000 | $1,058,000 | $-18,658,000 |
| Change In Inventory | $-28,401,000 | $-2,542,000 | $19,087,000 | $-24,947,000 |
| Change In Receivables | $4,046,000 | $994,000 | $11,297,000 | $-24,027,000 |
| Changes In Account Receivables | $4,046,000 | $994,000 | $11,297,000 | $-24,027,000 |
| Other Non Cash Items | $17,440,000 | $1,504,000 | $-62,619,000 | $37,956,000 |
| Stock Based Compensation | $7,775,000 | $9,317,000 | $17,849,000 | $22,735,000 |
| Provisionand Write Offof Assets | $4,208,000 | $1,580,000 | $30,242,000 | - |
| Asset Impairment Charge | $876,000 | $0 | $30,242,000 | $36,624,000 |
| Depreciation Amortization Depletion | $37,504,000 | $37,627,000 | $37,697,000 | $37,970,000 |
| Depreciation And Amortization | $37,504,000 | $37,627,000 | $37,697,000 | $37,970,000 |
| Amortization Cash Flow | $36,042,000 | $36,042,000 | $36,043,000 | $36,043,000 |
| Amortization Of Intangibles | $36,042,000 | $36,042,000 | $36,043,000 | $36,043,000 |
| Depreciation | $1,462,000 | $1,585,000 | $1,654,000 | $1,927,000 |
| Gain Loss On Investment Securities | $330,000 | $-760,000 | $-1,060,000 | $-600,000 |
| Net Income From Continuing Operations | $-69,410,000 | $-51,925,000 | $-94,226,000 | $-282,024,000 |
| Change In Other Working Capital | - | $-3,738,000 | $4,654,000 | $1,821,000 |
| Net Investment Purchase And Sale | - | - | $0 | $40,000,000 |
| Sale Of Investment | - | - | $0 | $40,000,000 |
| Purchase Of Investment | - | - | $0 | $0 |
| Amortization Of Securities | - | - | $0 | $-15,000 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |